COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #152
Source   PDF   Share   Tweet
See all 181 studies
10/21
Inconc.
Late treatment study
Lano et al., Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199 (Peer Reviewed)
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort
33% lower mortality with HC Q+AZ, p=0.28. Retrospective 122 French dialysis patients.
69% lower combined mortality/ICU, p=0.11, for the subgroup not requiring O2 on diagnosis (slightly earlier treatment).
death, ↓33.1%, p=0.28
combined death/ICU, ↓38.9%, p=0.23
combined death/ICU, ↓68.7%, p=0.11, not requiring O2 on diagnosis
(odds ratio converted to relative risk)
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit